Dr. Jones is an immunologist focusing on oncology and therapeutic vaccine development. He is the PI on over $20 million awarded grants and contracts from the NIH and DOD to develop the Etubics Platform (Ad5 [E1-, E2b-] ) vectors and test them in clinical trials. He initiated the “first in man” FDA approved Phase I/II clinical trial using an Ad5 [E1-, E2b-]-CEA product to treat colorectal cancer patients. The trial results demonstrated the safety of the novel platform and better than expected overall survival. He leads the team that has constructed and developed eight platform disease targets and tested them in several different animal models and humans. He is named inventor on issued patents and an author of many peer reviewed scientific publications, most describing vaccine agents or treatment of cancers. On the business side, Jones has been the founder and CEO of three companies including Etubics Corporation. He has assembled a multi-center team of individuals with expertise in cancer immunotherapy, pre-clinical applications, GMP manufacturing, clinical trial design and experience and commercial manufacturing of large quantities of vaccines and immunotherapeutics. Together, they are bringing immunotherapy targets from the bench to the bedside and through the regulatory process.